Increased expression of renal neutral endopeptidase in severe heart failure

Life Sciences

Volumn 71, Issue 23, 2002, Pages 2701-2712

  Knecht, Mathias ^a   Pagel, Ines ^b   Langenickel, Thomas ^b   Philipp, Sebastian ^b   Scheuermann Freestone, Michaela ^b   Willnow, Thomas ^c   Bruemmer, Dennis ^d   Graf, Kristof ^d   Dietz, Rainer ^b   Willenbrock, Roland ^b,e  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^e Krankenhaus St Elisabeth und St Barbara   (Germany)

Author keywords

Enzyme (kinetics); Heart failure; Hormones; Natriuretic peptide; Water electrolyte balance

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; AORTOCAVAL FISTULA; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE ENDDIASTOLIC PRESSURE; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BASE SEQUENCE; CYCLIC GMP; DNA PRIMERS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; KIDNEY; MALE; NEPRILYSIN; POLYMERASE CHAIN REACTION; RATS; RATS, WISTAR; RNA, MESSENGER;

ANIMALIA; TRIXIS;

EID: 18644365706     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)01990-2     Document Type: Article

References (44)

1. Schulz R., Sakane Y., Berry C., Ghai R. Characterisation of neutral endopeptidase 3.4.24.11 (NEP) in the kidney: comparison between normotensive, genetically hypertensive rats. J Enzyme Inhib. 4:1991;347-358.
2. Abassi Z.A., Tate J.E., Golomb E., Keiser H.R. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension. 20:1992;89-95.
3. Ura N., Carretero O.A., Erdös E.G. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int. 32:1987;507-513.
4. Lu B., Figini M., Emanueli C., Geppetti P., Grady E.F., Gerard N.P., Ansell J., Payan D.G., Gerard C., Bunnett N. The control of microvascular permeability and blood pressure by neutral endopeptidase. Nat Med. 3:1997;904-907.
5. Sonnenberg J.L., Sakane Y., Jeng A.Y., Koehn J.A., Ansell J.A., Wennogle L.P., Ghai R.D. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides. 9:1988;173-180.
6. Winaver J., Hoffman A., Burnett J.C. Jr., Haramati A. Hormonal determinants of sodium excretion in rats with experimental high-output heart failure. Am J Physiol. 254:1988;R776-R784.
7. Cody R.J., Atlas S.A., Laragh J.H., Kubo S.H., Covit A.B., Ryman K.S., Shaknovich A., Pondolfino K., Clark M., Camargo M.J.F., Scarborough R.M., Lewicki J.A. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest. 78:1986;1362-1374.
8. Redfield M.M., Edwards B.S., Heublein D.M., Burnett J.C. Jr. Restoration of renal response to atrial natriuretic factor in experimental low-output heart failure. Am J Physiol. 257:1989;R917-R923.
9. Riegger G.A., Kromer E.P., Wild S., Hofbauer H., Klug M.L., Kochsiek K. Atrial natriuretic factor in acute and chronic cardiac failure. J Cardiovasc Pharmacol. 10:1987;S161-S165.
10. Margulies K.B., Heublein D.M., Perrella M.A., Burnett J.C. Jr. ANF-mediated renal cGMP generation in congestive heart failure. Am J Physiol. 260:1991;F562-F568.
11. Cavero P.G., Margulies K.B., Winaver J., Seymour A.A., Delaney N.G., Burnett J.C. Jr. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation. 82:1990;196-201.
12. Burnett J.C. Jr., Kao P.C., Hu D.C., Heser D.W., Heublein D., Granger J.P., Opgenorth T.J., Reeder G.S. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 231:1986;1145-1147.
13. Raine A.E., Erne P., Bürgisser E., Müller F.B., Bolli P., Burkart F., Bühler F.R. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med. 315:1986;533-537.
14. Abassi Z., Burnett J.C. Jr., Grushka E., Hoffman A., Haramati A., Winaver J. Atrial natriuretic peptide and renal cGMP in rats with experimental heart failure. Am J Physiol. 261:1991;R858-R864.
15. Yechieli H., Kahana L., Haramati A., Hoffman A., Winaver J. Regulation of renal glomerular and papillary ANP receptors in rats with experimental heart failure. Am J Physiol. 265:1993;F119-F125.
16. Tsunoda K., Mendelsohn F.A., Sexton P.M., Chai S.Y., Hodsman G.P., Johnston C.I. Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure. Circ Res. 62:1988;155-161.
17. Kukkonen P., Vuolteenaho O., Ruskoaho H. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: Effects of SCH 39.370, an endopeptidase inhibitor, and C- ANF-(4-23), a clearance receptor ligand. Endocrinology. 130:1992;755-765.
18. Charles C.J., Espiner E.A., Nicholls M.G., Richards A.M., Yandle T.G., Protter A., Kosoglou T. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol. 271:1996;R373-R380.
19. Rademaker M.T., Charles C.J., Kosoglou T., Protter A.A., Espiner E.A., Nicholls M.G., Richards A.M. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Am J Physiol. 273:1997;H2372-H2379.
20. Perrella M.A., Margulies K.B., Wei C.-M., Aarhus L.L., Heublein D.M., Burnett J.C. Jr. Pulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs. J Clin Invest. 87:1991;1649-1655.
21. Wilkins M.R., Settle S.L., Stockmann P.T., Needleman P. Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc Natl Acad Sci USA. 87:1990;6465-6469.
22. Northridge D.B., Alabaster C.T., Connell J.M.C., Dilly S.G., Lever A.F., Jardine A.G., Barclay P.L., Dargie H.J., Findlay I.N., Samuels G.M. Effects of UK 69 578: A novel atriopeptidase inhibitor. Lancet. 1989;591-593.
23. Trippodo N.C., Gabel R.A., Harvey C.M., Asaad M.M., Rogers W.L. Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats. J Cardiovasc Pharmacol. 18:1991;308-316.
24. Margulies K.B., Barclay P.L., Burnett J.C. Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation. 91:1995;2036-2042.
25. Garcia R., Diebold S. Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res. 24:1990;430-432.
26. Willenbrock R., Scheuermann M., Höhnel K., Luft F.C., Dietz R. Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt. Hypertension. 27:1996;1259-1266.
27. Gutkowska J., Bonan R., Roy D., Bourassa M., Garcia R., Thibault G., Genest J., Cantin M. Atrial natriuretic factor in human plasma. Biochem Biophys Res Commun. 139:1986;287-295.
28. Florentin D., Sassi A., Roques B.P. A highly sensitive fluorometric assay for "enkephalinase", a neutral metalloendopeptidase that releases tyrosine-glycine-glycine from enkephalins. Methods Enzymol. 1983;62-69.
29. Heder G., Böttger A., Siems W.E., Halatsch W.-R., Steinmann C. Zur Bestimmung von neutraler Metalloendopeptidase (Enkephalinase A) in biologischem Material. Pharmazie. 43:1988;637-639.
30. Abassi Z.A., Kotob S., Golomb E., Pieruzzi F., Keiser H.R. Pulmonary and renal neutral endopeptidase EC 3.4.24.11 in rats with experimental heart failure. Hypertension. 25:1995;1178-1184.
31. Wegner M., Hirth-Dietrich C., Stasch J.-P. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. Cardiovasc.Res. 31:1996;891-898.
32. Margulies K.B., Cavero P.G., Seymour A.A., Delaney N.G., Burnett J.C. Jr. Neutral endopeptidase inhibition potentiates the renal action of atrial natriuretic factor. Kidney Int. 38:1990;67-72.
33. Trapani A.J., Smits G.J., McGraw D.E., Spear K.L., Koepke J.P., Olins G.M., Blaine E.H. Thiorphan, an inhibitor of endopeptidase 24.11, potentiates the natriuretic activity of atrial natriuretic peptide. J Cardiovasc Pharmacol. 14:1989;419-424.
34. Chen H.H., Schirger J.A., Chau W.L., Jougasaki M., Lisy O., Redfield M.M., Barclay P.T., Burnett J.C. Jr. Renal response to acute neural endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 100:1999;2443-2448.
35. Fielitz J., Dendorfer A., Pregla R., Ehler E., Zurbrügg H.R., Bartunek J., Hetzer R., Regitz-Zagrosek V. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation. 105:2002;286-289.
36. Matsumura T., Kugiyama K., Sugiyama S., Ohgushi M., Yamanaka K., Suzuki M., Yasue H. Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxity. J Clin Invest. 97:1996;2192-2203.
37. Edwards R.M., Pullen M., Nambi P. Distribution od neutral endopeptidase activity along the rat and rabbit nephron. Pharmacology. 59:1999;45-50.
38. Knecht M., Scheuermann M., Philipp S., Willenbrock R. Increased renal activity of neutral endopeptidase correlates with plasma ANP in different models of experimental left ventricular dysfunction. Circulation. 100(Suppl. 1):1999;I-533.
39. Roques B.P., Noble F., Dauge V., Fournie-Zaluski M.C., Beaumont A. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 45:1993;87-144.
40. Huang H., Arnal J.-F., LIorens-Cortes C., Challah M., Alhenc-Gelas F., Corvol P., Michel J.-B. Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental congestive heart failure. Circ Res. 75:1994;454-461.
41. Matsukawa N., Grzesik W.J., Takahashi N., Pandey K.N., Pang S., Yamauchi M., Smithies O. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA. 96:1999;7403-7408.
42. Nagase M., Ando K., Katafuchi T., Kato A., Hirose S., Fujita T. Role of natriuretic peptide receptor type C in dahl salt-sensitive hypertensive rats. Hypertension. 30:1997;177-183.
43. Chiu P.J., Tetzloff G., Romano M.T., Foster C.J., Sybertz E.J. Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats. Am J Physiol. 260:1991;R208-R216.
44. Andreassi M.G., Ry S.D., Palmieri C., Clerico A., Biagini A., Giannessi D. Up - regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur J Heart Fail. 3:2001;407-414.